Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

digital tools

- PMLiVE

FDA approves Rigel’s Rezlidhia for acute myeloid leukaemia

Phase 2 data showed a complete remission rate of 35% and median duration of 25.9 months

- PMLiVE

GSK’s Jemperli shows promise in phase 3 endometrial cancer trial

An interim analysis noted the trial met its primary endpoint of progression-free survival

- PMLiVE

AZ and MSD launch ‘Never Miss’ for prostate cancer awareness

Prostate cancer is often symptomless and is the second most common cancer in men globally

- PMLiVE

Cancer Research Horizons and the Karolinska Institutet announce five-year strategic partnership

The collaboration will aim to accelerate the translation of cancer research into clinical practice

- PMLiVE

DIGITAL HEALTH IN PRACTICE AND OVERCOMING DIGITAL FATIGUE

During this year’s Reuters event, Pharma 2022, WebMD CMO, Dr John Whyte discussed the ways in which digital health is growing, and the importance of educating clinicians in the right...

Medscape Education Global

- PMLiVE

AstraZeneca to acquire Neogene Therapeutics in $320m deal

The agreement will build the company’s pipeline of cell-based cancer treatments

- PMLiVE

Medscape Medical Affairs Celebrate a Double Win at the PMEAs

Last night the Medscape Medical Affairs team gathered in London for the Pharmaceutical Market Excellence Awards (PMEAs) where their entry, Transatlantic Exchanges: Driving Therapeutic Innovation in Oncology for the Benefit of...

Medscape Medical Affairs

- PMLiVE

Precision medicine trial opens for patients with rare cancers

Rare cancers make up 22% of cancers that are diagnosed globally each year, more than any single type of cancer

- PMLiVE

Kate Shaw reflects on Innovative Trials’ first US office openings

On Thanksgiving, Kate Shaw, Founder and CEO of Innovative Trials, reflects on the company first US office opening

Innovative Trials

- PMLiVE

Cancer Research Horizons and Newcastle University extend alliance with Astex

The agreement will extend the current alliance between the three parties by a further five years

- PMLiVE

ICR and The Royal Marsden reveal plans to ‘disrupt’ cancer ecosystems

The researchers aim to double survival for people with advanced cancer within a decade

- PMLiVE

BeiGene’s Brukinsa receives EC approval for chronic lymphocytic leukaemia

The drug showed better results than Imbruvica, a current standard of care treatment

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links